Patents by Inventor Martin Matzuk

Martin Matzuk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230192606
    Abstract: Novel direct thrombin inhibitors are provided herein, along with methods for their use as anticoagulants. The direct thrombin inhibitors described herein are useful in treating and/or preventing thromboembolism and bleeding or clotting disorders. Also provided herein are methods for inhibiting thrombin in a cell using the compounds and compositions described herein.
    Type: Application
    Filed: April 16, 2021
    Publication date: June 22, 2023
    Applicant: Baylor College of Medicine
    Inventors: Martin Matzuk, Surendra Dawadi, Melek Ucisik, John Faver, Kurt Bohren, Feng Li
  • Patent number: 9789120
    Abstract: The invention relates to compositions and methods for effecting male contraception.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: October 17, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Baylor College of Medicine
    Inventors: James Elliott Bradner, Martin Matzuk, Jun Qi
  • Publication number: 20160317547
    Abstract: The invention relates to compositions and methods for effecting male contraception.
    Type: Application
    Filed: December 21, 2015
    Publication date: November 3, 2016
    Inventors: James Elliott Bradner, Martin Matzuk, Jun Qi
  • Patent number: 9301962
    Abstract: The invention relates to compositions and methods for effecting male contraception.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: April 5, 2016
    Assignees: Baylor College of Medicine, Dana Farber Cancer Institute, Inc.
    Inventors: James Elliott Bradner, Martin Matzuk, Jun Qi
  • Publication number: 20130210813
    Abstract: The invention relates to compositions and methods for effecting male contraception.
    Type: Application
    Filed: May 16, 2011
    Publication date: August 15, 2013
    Inventors: James Elliott Bradner, Martin Matzuk, Jun Qi
  • Publication number: 20080081780
    Abstract: The present invention relates to compositions and methods for modulating conception in animals. More particularly, the composition modulates mRNA degradation during gametogenesis and early development. Yet further, the present invention relates to pharmaceutical compositions and methods for modulating diseases of the reproductive organs, such as hyperproliferative diseases.
    Type: Application
    Filed: June 17, 2007
    Publication date: April 3, 2008
    Inventors: Martin Matzuk, Yuchen Bai, Wei Yan
  • Publication number: 20070264714
    Abstract: Isolated GDF-9 regulatory sequences are disclosed, as well as methods of using the sequences to modulate tissue-specific expression of genes. The GDF-9 regulatory sequences include, for example, enhancer and promoter elements that naturally drive transcription of GDF-9 in specific tissues. The GDF-9 regulatory sequences can be derived from the untranscribed upstream (e.g., first 10 kilobases) and downstream regions, and transcribed, untranslated regions of a GDF-9 gene.
    Type: Application
    Filed: March 26, 2007
    Publication date: November 15, 2007
    Applicant: MetaMorphix, Inc.
    Inventors: Martin Matzuk, Julia Elvin
  • Publication number: 20060223099
    Abstract: The present invention is related to TEX14 and germ cell intercellular bridges and compositions thereof that can be used to inhibit and/or decrease the activity and/or expression of TEX14 and/or disrupt the formation, function, and/or integrity of the intercellular bridges, including localization of key components to the intercellular bridge, for example. In particular aspects, the methods and compositions are employed for fertility and infertility applications.
    Type: Application
    Filed: March 30, 2006
    Publication date: October 5, 2006
    Applicant: BAYLOR COLLEGE OF MEDICINE
    Inventors: Martin Matzuk, Michael Greenbaum, Aleksandar Rajkovic
  • Publication number: 20060079674
    Abstract: The present invention relates generally to ovary-specific genes (O1-180, O1-184 and O1-236) and the proteins they encode. Also provided are methods for detecting cell proliferative or degenerative disorders in reproductive tissues. Yet further, the invention provides methods for scrounge of compounds that interact and/or modulate the expression or activity of the ovary-specific genes. These compounds are possible contraceptive agents and/or fertility agents.
    Type: Application
    Filed: October 14, 2004
    Publication date: April 13, 2006
    Inventors: Martin Matzuk, Yuchen Bai, Pei Wang, Xuemei Wu
  • Publication number: 20060069243
    Abstract: Ovary specific proteins O1 180, O1 184 and O1 236, polynucleotides encoding them, antibodies which are immunoreactive with them and vectors and host cells containing O1 180, O1 184 or O1 236 are provided. Also provided are methods for detecting cell proliferative or degenerative disorders of ovarian origin and which are associated with O1 180, O1 184 or O1 236. Further provided are methods for the evaluation of potential contraceptives using the proteins of the invention, as well as methods for the screening for genetic mutations in signaling pathways that are associated with some forms of human infertility or gynecological cancers, also using the proteins/mRNAs/genes of the invention. The proteins/mRNAs/genes of the invention may also be used as markers for identifying primary and metastatic neoplasms of ovarian origin and as indicators of developmental anomalies in prenatal screening procedures.
    Type: Application
    Filed: November 9, 2005
    Publication date: March 30, 2006
    Inventors: Martin Matzuk, Pei Wang
  • Publication number: 20040204338
    Abstract: The present invention highlights the role of acetyl-CoA carboxylase through its product malonyl-CoA in regulating fatty acid oxidation and synthesis, glucose metabolism and energy homeostasis. It discloses transgenic mice with inactivating mutations in the endogenous gene for the acetyl-CoA carboxylase 2 isoform of acetyl-CoA carboxylase. Inactivation of acetyl-CoA carboxylase 2 results in mice exhibiting a phenotype of reduced malonyl-CoA levels in skeletal muscle and heart, unrestricted fat oxidation, and reduced fat accumulation in the liver and fat storage cells. As a result, the mice consume more food but accumulate less fat and remain leaner than wild-type mice fed the same diet. These results demonstrate that inhibition of ACC2 acetyl-CoA carboxylase could be used to regulate fat oxidation and accumulation for purposes of weight control.
    Type: Application
    Filed: January 16, 2004
    Publication date: October 14, 2004
    Applicant: Research Development Foundation
    Inventors: Salih J. Wakil, Lutfi Abu-Elheiga, Martin Matzuk
  • Patent number: 6734337
    Abstract: The present invention highlights the role of acetyl-CoA carboxylase through its product malonyl-CoA in regulating fatty acid oxidation and synthesis, glucose metabolism and energy homeostasis. It discloses transgenic mice with inactivating mutations in the endogenous gene for the acetyl-CoA carboxylase 2 isoform of acetyl-CoA carboxylase. Inactivation of acetyl-CoA carboxylase 2 results in mice exhibiting a phenotype of reduced malonyl-CoA levels in skeletal muscle and heart, unrestricted fat oxidation, and reduced fat accumulation in the liver and fat storage cells. As a result, the mice consume more food but accumulate less fat and remain leaner than wild-type mice fed the same diet. The instant invention provides a useful animal model to regulate malonyl-CoA production by ACC2 in the regulation of fatty acid oxidation by muscle, heart, liver and other tissues. They also identify potential inhibitors for studying the mechanisms of fat metabolism and weight control.
    Type: Grant
    Filed: August 14, 2001
    Date of Patent: May 11, 2004
    Assignee: Research Development Foundation
    Inventors: Salih J. Wakil, Martin Matzuk, Lutfi Abu-Elheiga
  • Publication number: 20020112253
    Abstract: The present invention highlights the role of acetyl-CoA carboxylase through its product malonyl-CoA in regulating fatty acid oxidation and synthesis, glucose metabolism and energy homeostasis. It discloses transgenic mice with inactivating mutations in the endogenous gene for the acetyl-CoA carboxylase 2 isoform of acetyl-CoA carboxylase. Inactivation of acetyl-CoA carboxylase 2 results in mice exhibiting a phenotype of reduced malonyl-CoA levels in skeletal muscle and heart, unrestricted fat oxidation, and reduced fat accumulation in the liver and fat storage cells. As a result, the mice consume more food but accumulate less fat and remain leaner than wild-type mice fed the same diet. These results demonstrate that inhibition of ACC2 acetyl-CoA carboxylase could be used to regulate fat oxidation and accumulation for purposes of weight control.
    Type: Application
    Filed: August 14, 2001
    Publication date: August 15, 2002
    Inventors: Salih J. Wakil, Martin Matzuk, Lutfi Abu-Elheiga